Back to top

gene-editing: Archive

Zacks Equity Research

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'

RHHBYNegative Net Change SRPTPositive Net Change ANIPPositive Net Change CTMXPositive Net Change

Zacks Equity Research

Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.

BMRNPositive Net Change GILDPositive Net Change VRTXPositive Net Change EDITPositive Net Change

Zacks Equity Research

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

SRPT reports mixed fourth-quarter 2024 results. It closes the multi-billion-dollar deal with Arrowhead and adds four new clinical programs to its pipeline.

RHHBYNegative Net Change SRPTPositive Net Change ARWRNegative Net Change

Zacks Equity Research

CRISPR Therapeutics Q4 Earnings and Revenues Surpass Estimates

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

ALNYPositive Net Change BMRNPositive Net Change VRTXPositive Net Change CRSPPositive Net Change